Search Weight Loss Topics:




Dec 14

St. Louis Health Alert: Should I Keep Taking Tirzepatide for Weight Loss Success? Doctor Explains – Branson Tri-Lakes news

Long Term Weight Loss Comments Off on St. Louis Health Alert: Should I Keep Taking Tirzepatide for Weight Loss Success? Doctor Explains – Branson Tri-Lakes news

The Big Picture: Dr. Adriana Davis, Family Medicine, "The idea here is to know that drugs like Ozempic and Mounjaro are being used for chronic disease conditions--and you may have to take these medicines indefinitely." Doctor's Expert Insights About Weight Loss and Drugs like Tirzepatide and Ozempic in Missouri

Know this: "So, this study shows significant weight loss with tirzepatide, but highlights a challenge: stopping the drug often leads to weight regain. This isn't about willpower--it's about understanding that obesity is a chronic condition that may require ongoing medication. Like many other chronic diseases, obesity needs to be managed. It will require ongoing pharmacotherapy and lifestyle changes. This study serves as a reminder that weight management is a long-term commitment and requires sustained medical and lifestyle interventions. Also, as I've been recommending here, make sure that you know your A1C and blood cholesterol levels. Knowing these metrics will be important in guiding how you and your healthcare team treat and manage obesity." Dr. Puja Uppal, Family Medicine.

Beyond the news: These findings are creating a paradigm shift in how obesity is treated and managed--with an emphasis on long-term pharmacological intervention and lifestyle changes.

Key Findings:

"After 36 weeks of open-label maximum tolerated dose of tirzepatide (10 or 15 mg), adults (n=670) with obesity or overweight (without diabetes) experienced a mean weight reduction of 20.9%. From randomization (at week 36), those switched to placebo experienced a 14% weight regain and those continuing tirzepatide experienced an additional 5.5% weight reduction during the 52-week double-blind period." (Study Source)

Key Drivers in St. Louis County:

The study highlighted tirzepatide's efficacy in maintaining and augmenting initial weight loss in individuals who were overweight.

Participants that continued tirzepatide after an initial 36-week period experienced an additional 5.5% weight reduction of their body weight. But, those who were switched to a placebo regained an average of 14.4% of their body weight.

The study also noted improvements in cardiometabolic risk factors with tirzepatide use--this is significant for overall health outcomes.

What they're saying: "The consistency of these data across therapeutic classes spanning more than 2 decades suggests that obesity is a chronic metabolic condition similar to type 2 diabetes and hypertension requiring long-term therapy in most patients.

A notable finding in the SURMOUNT-4 trial is that after switching to placebo for 1 year, participants ended the study with substantial body weight reduction (9.9%). However, much of their initial improvement in cardiometabolic risk factors had been reversed. Further studies are needed to understand the potential long-term benefits and risks (ie, legacy effects) of such short-term therapy." (Study Source)

Health Standard Newswire: To keep the advantages gained from weight loss medications, it may be necessary to continue using them for the long term.

All of these variables above play an important role in the outcomes of your overall health.

The Health Standard Newswire.

Continued here:
St. Louis Health Alert: Should I Keep Taking Tirzepatide for Weight Loss Success? Doctor Explains - Branson Tri-Lakes news

Related Posts

    Your Full Name

    Your Email

    Your Phone Number

    Select your age (30+ only)

    Select Your US State

    Program Choice

    Confirm over 30 years old

    Yes

    Confirm that you resident in USA

    Yes

    This is a Serious Inquiry

    Yes

    Message:



    matomo tracker